SCCP.F Stock Overview
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
SciClone Pharmaceuticals (Holdings) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.83 |
| 52 Week High | HK$0.83 |
| 52 Week Low | HK$0.83 |
| Beta | 0.44 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCCP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 3.3% |
| 1Y | n/a | 12.6% | 25.8% |
Return vs Industry: Insufficient data to determine how SCCP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SCCP.F performed against the US Market.
Price Volatility
| SCCP.F volatility | |
|---|---|
| SCCP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SCCP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SCCP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 1,000 | Hong Zhao | www.sciclone.com |
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company’s proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company’s pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer.
SciClone Pharmaceuticals (Holdings) Limited Fundamentals Summary
| SCCP.F fundamental statistics | |
|---|---|
| Market cap | US$719.51m |
| Earnings (TTM) | US$131.33m |
| Revenue (TTM) | US$396.46m |
5.5x
P/E Ratio1.8x
P/S RatioIs SCCP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCCP.F income statement (TTM) | |
|---|---|
| Revenue | CN¥2.88b |
| Cost of Revenue | CN¥746.87m |
| Gross Profit | CN¥2.13b |
| Other Expenses | CN¥1.18b |
| Earnings | CN¥953.34m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.60 |
| Gross Margin | 74.05% |
| Net Profit Margin | 33.13% |
| Debt/Equity Ratio | 30.7% |
How did SCCP.F perform over the long term?
See historical performance and comparison